Cabometyx tablets and Cometriq capsules are both cabozantinib, but the FDA label says do not substitute one for the other.
Cabometyx (cabozantinib tablets) and Cometriq (cabozantinib capsules) share the same active ingredient but carry separate FDA approvals, separate strengths and separate dosing schedules. M Care sources both, by brand, through Exelixis's licensed Indian distribution channels, as a merchant exporter, not a manufacturer. Tell us which brand your tender or hospital formulary specifies; we do not treat them as interchangeable and neither should a buyer.
Cabozantinib exporter and bulk supplier from India.
For tender and bulk hospital orders, M Care confirms brand, strength and pack configuration against the destination country's own registration before booking any cabozantinib consignment. Cabometyx moves as single-strength tablet packs (20 mg, 40 mg or 60 mg); Cometriq moves as a combination kit of 20 mg and 80 mg capsules assembled to the prescribed daily dose. Both are patent-protected Exelixis products, so supply runs through licensed Indian distribution channels rather than generic manufacturing lines. We flag country-specific oncology import licensing (narcotics-style controlled distribution does not apply here, but named-patient or hospital-exemption routes often do) before dispatch is scheduled.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Tyrosine kinase inhibitor (MET, VEGFR-2, AXL, RET), sourced and documented for export.
Cabozantinib is a small-molecule tyrosine kinase inhibitor. It blocks MET, VEGFR-2, AXL and RET signalling, targets exploited by several solid tumours to drive angiogenesis and invasion.
Cabometyx tablets are FDA-licensed for advanced renal cell carcinoma (RCC), including first-line use in combination with nivolumab; for hepatocellular carcinoma (HCC) previously treated with sorafenib; for locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed on VEGFR-targeted therapy in patients 12 years and older who are radioactive-iodine-refractory or ineligible; and, since March 2025, for previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumours (NET) in patients 12 years and older. Cometriq capsules carry a separate, narrower licence: progressive, metastatic medullary thyroid cancer (MTC) only.
Both are oral solids. Cabometyx tablets come in 20 mg, 40 mg and 60 mg strengths; Cometriq is supplied as a kit of 20 mg and 80 mg capsules. Neither needs cold chain: both are stored at 20-25C (68-77F), with excursions permitted to 15-30C, and shipped as standard ambient pharmaceutical cargo.
Active ingredient
cabozantinib. Tyrosine kinase inhibitor (MET, VEGFR-2, AXL, RET).
Forms and strengths
20 mg tablet (Cabometyx); 40 mg tablet (Cabometyx); 60 mg tablet (Cabometyx); 20 mg capsule (Cometriq); 80 mg capsule (Cometriq).
Indications
Cabometyx tablets are licensed for advanced renal cell carcinoma, hepatocellular carcinoma previously treated with sorafenib, differentiated thyroid cancer progressing on VEGFR-targeted therapy, and previously treated pancreatic and extra-pancreatic neuroendocrine tumours; Cometriq capsules are licensed for progressive metastatic medullary thyroid cancer.
Administration
oral. Film-coated tablets (Cabometyx) or capsules (Cometriq).
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers for cabozantinib fall into two groups that should not be conflated: oncology-centre pharmacy teams and MoH tender desks sourcing Cabometyx for RCC, HCC, DTC or neuroendocrine tumour treatment pathways, and the smaller, more specialised group of endocrine-oncology units and thyroid cancer referral centres sourcing Cometriq specifically for MTC. NHS trust buyers, GCC MoH tender desks (SFDA in Saudi Arabia, MOHAP in the UAE), African referral hospitals and licensed private importers all approach M Care for one brand or the other; we ask which indication is driving the order before quoting, since it determines the correct product.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on cabozantinib.
Confirm the indication before confirming the brand. Cabometyx (tablets) covers RCC, HCC, DTC and neuroendocrine tumours; Cometriq (capsules) is licensed only for progressive metastatic MTC. A formulary substitution between them is not supported by the label: the FDA prescribing information states plainly not to substitute Cometriq capsules with cabozantinib tablets, and the labelling separately notes a roughly 19% higher Cmax for the tablet formulation versus the capsule formulation at matched doses.
Food timing differs by a narrow margin but both require a fasted window. Cabometyx: administer at least 1 hour before or at least 2 hours after eating. Cometriq: instruct patients not to eat for at least 2 hours before and at least 1 hour after dosing. Mixing up the two fasting windows on a ward medication chart is an easy transcription error worth flagging at reconciliation.
Dosing is once daily but the numbers are brand-specific and strength-specific. Cabometyx monotherapy starts at 60 mg once daily; in combination with nivolumab for first-line RCC, the Cabometyx dose is 40 mg once daily, with dose reduction on adverse reactions to 20 mg once daily, then 20 mg every other day if a further reduction is needed. Cometriq starts at 140 mg once daily (built from the 80 mg plus three 20 mg capsules in the kit), reducing to 100 mg then 60 mg once daily on toxicity, using the same two capsule strengths in different combinations.
No cold chain is required for either brand; both are stored at controlled room temperature, 20-25C with permitted excursions to 15-30C. That simplifies logistics but does not simplify the ordering decision: get the brand name, strength and combination-therapy status confirmed in writing before we release a consignment.
The documentation pack a regulator actually asks for.
Both Cabometyx and Cometriq are Exelixis-originated, patent-protected products. No FDA-licensed generic exists for either brand today; two alternate cabozantinib formulations have received FDA tentative approval only (a status that does not permit US marketing until FDA issues a final approval letter), and M Care does not represent either of them. Supply runs through Exelixis's licensed Indian distribution channels, verified against the destination market's own product registration or named-patient import route before we quote.
As oral solid dosage forms, the documentation chain is the standard pharmaceutical export set: CDSCO export licensure on the Indian side, manufacturer batch certificates of analysis, and the destination country's own import permit or hospital-exemption paperwork, most commonly required where a market's MoH has not separately registered both cabozantinib brands. Because the two products are not interchangeable on the label, tender documentation and import permits must name the specific brand, not just the INN, to avoid a mismatched consignment at customs.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside cabozantinib.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for cabozantinib.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Cabozantinib supply, the specific questions.
Is there a generic version of cabozantinib?
No, not one that is currently FDA-licensed for marketing. Both Cabometyx (tablets) and Cometriq (capsules) remain patent-protected Exelixis products; two alternate cabozantinib formulations from other manufacturers hold FDA tentative approval only, which does not allow them to be marketed until final approval is granted. M Care sources both brands through licensed Indian distribution channels, not through generic manufacturing lines.
Can I substitute Cometriq capsules for Cabometyx tablets, or vice versa?
No. The FDA prescribing information explicitly states Cometriq capsules should not be substituted with cabozantinib tablets. The two formulations have different pharmacokinetics (the tablet shows a roughly 19% higher peak concentration at matched doses) and are licensed for different indications, so a formulary swap is not supported.
Which cabozantinib brand do I need for renal cell carcinoma or hepatocellular carcinoma?
Cabometyx tablets. Cabometyx is licensed for advanced RCC (including first-line combination with nivolumab) and for HCC previously treated with sorafenib. Cometriq is not licensed for either indication.
Which brand covers medullary thyroid cancer?
Cometriq capsules are licensed specifically for progressive, metastatic medullary thyroid cancer. Cabometyx tablets are licensed for differentiated thyroid cancer, a different thyroid cancer subtype with a different label. Confirm the histology before ordering.
Does Cabometyx cover neuroendocrine tumours?
Yes. Since March 2025, Cabometyx tablets are also FDA-licensed for previously treated, unresectable, locally advanced or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumours in patients 12 years and older. Cometriq is not licensed for this indication.
Does cabozantinib need cold-chain shipping?
No. Both Cabometyx tablets and Cometriq capsules are stored at controlled room temperature, 20-25C with excursions permitted to 15-30C, and ship as standard ambient pharmaceutical cargo, not as a cold-chain consignment.
Can M Care supply Cabometyx or Cometriq to our market?
Yes, on an import basis matched to your country's own registration status. M Care is a merchant exporter and sources both brands through licensed Indian distribution channels; we confirm the applicable import route (direct registration, named-patient, or hospital-exemption) for your destination market before dispatch.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-08-28.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.